Drugs / C6 Ceramide
C6 Ceramide
also known as
CNL · C6 ceramide nanoliposome · Ceramide NanoLiposome · Ceramide nanoLiposomes · Ceraxa
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04716452 | Oct 2025 → Sep 2026 overdue | acute myeloid leukemia | Keystone Nano, Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT02834611 | Mar 2017 → Aug 2023 | carcinoma | Keystone Nano, Inc | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C6 Ceramide | “The research team has shown that C6 ceramide nanoliposome (CNL) has anti-cancer activity in laboratory models of AML” NCT04716452 ↗1“Phase I Study of C6 Ceramide NanoLiposome in Patients With Advanced Solid Tumors” NCT02834611 ↗ |
| Known as | C6 ceramide nanoliposome | “The research team has shown that C6 ceramide nanoliposome (CNL) has anti-cancer activity in laboratory models of AML” NCT04716452 ↗ |
| Known as | Ceramide NanoLiposome | “The research team has shown that C6 ceramide nanoliposome (CNL) has anti-cancer activity in laboratory models of AML” NCT04716452 ↗ |
| Known as | Ceramide nanoLiposomes | “This phase I dose-escalation trial evaluated Ceramide nanoLiposomes (CNL) in patients with advanced solid tumors and no standard treatment option.” PMID 37736793 ↗ Sep 2023 |
| Known as | Ceraxa | “KN, who holds the IND for the phase I clinical trial, is developing CNL as Ceraxa™.” PMID 37736793 ↗ Sep 2023 |
| Known as | CNL | “This phase I dose-escalation trial evaluated Ceramide nanoLiposomes (CNL) in patients with advanced solid tumors and no standard treatment option.” PMID 37736793 ↗ Sep 20231“The research team has shown that C6 ceramide nanoliposome (CNL) has anti-cancer activity in laboratory models of AML” NCT04716452 ↗ |
| Route | Intravenous | “Intravenous administration of Ceramide NanoLiposome” NCT02834611 ↗ |